International Stem Cell Corporation (ISCO)
USD 0.12
(20.0%)
USD 0.12
(20.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.27 Million USD | -45.34% |
| 2022 | 9.65 Million USD | 1.27% |
| 2021 | 9.53 Million USD | -0.89% |
| 2020 | 9.62 Million USD | 1.18% |
| 2019 | 9.5 Million USD | 80.79% |
| 2018 | 5.25 Million USD | 9.56% |
| 2017 | 4.8 Million USD | 33.3% |
| 2016 | 3.6 Million USD | -35.05% |
| 2015 | 5.54 Million USD | -19.16% |
| 2014 | 6.85 Million USD | -42.67% |
| 2013 | 11.96 Million USD | 67.82% |
| 2012 | 7.12 Million USD | 237.18% |
| 2011 | 2.11 Million USD | 4.08% |
| 2010 | 2.03 Million USD | -58.18% |
| 2009 | 4.85 Million USD | 168.57% |
| 2008 | 1.8 Million USD | 30.54% |
| 2007 | 1.38 Million USD | 63.28% |
| 2006 | 848.46 Thousand USD | 11529.17% |
| 2005 | 7296.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.33 Million USD | 1.06% |
| 2024 Q2 | 5.31 Million USD | -0.43% |
| 2023 Q4 | 5.27 Million USD | -44.45% |
| 2023 Q2 | 9.63 Million USD | -1.58% |
| 2023 Q1 | 9.78 Million USD | 1.37% |
| 2023 Q3 | 9.5 Million USD | -1.37% |
| 2023 FY | 5.27 Million USD | -45.34% |
| 2022 FY | 9.65 Million USD | 1.27% |
| 2022 Q2 | 9.83 Million USD | -1.73% |
| 2022 Q3 | 9.69 Million USD | -1.42% |
| 2022 Q1 | 10 Million USD | 4.96% |
| 2022 Q4 | 9.65 Million USD | -0.4% |
| 2021 Q2 | 9.92 Million USD | -7.43% |
| 2021 Q3 | 9.29 Million USD | -6.32% |
| 2021 FY | 9.53 Million USD | -0.89% |
| 2021 Q4 | 9.53 Million USD | 2.58% |
| 2021 Q1 | 10.71 Million USD | 11.4% |
| 2020 Q4 | 9.62 Million USD | -1.1% |
| 2020 Q1 | 9.71 Million USD | 2.22% |
| 2020 Q2 | 10.38 Million USD | 6.88% |
| 2020 Q3 | 9.72 Million USD | -6.36% |
| 2020 FY | 9.62 Million USD | 1.18% |
| 2019 Q4 | 9.5 Million USD | 6.4% |
| 2019 Q3 | 8.93 Million USD | -8.18% |
| 2019 Q2 | 9.73 Million USD | 77.69% |
| 2019 FY | 9.5 Million USD | 80.79% |
| 2019 Q1 | 5.47 Million USD | 4.15% |
| 2018 Q4 | 5.25 Million USD | -11.45% |
| 2018 FY | 5.25 Million USD | 9.56% |
| 2018 Q2 | 6.77 Million USD | 16.19% |
| 2018 Q1 | 5.82 Million USD | 21.44% |
| 2018 Q3 | 5.93 Million USD | -12.31% |
| 2017 Q4 | 4.8 Million USD | -41.02% |
| 2017 Q3 | 8.13 Million USD | 35.18% |
| 2017 Q2 | 6.02 Million USD | -16.57% |
| 2017 FY | 4.8 Million USD | 33.3% |
| 2017 Q1 | 7.21 Million USD | 100.42% |
| 2016 Q3 | 7.11 Million USD | -19.54% |
| 2016 Q4 | 3.6 Million USD | -49.39% |
| 2016 FY | 3.6 Million USD | -35.05% |
| 2016 Q2 | 8.84 Million USD | -58.37% |
| 2016 Q1 | 21.24 Million USD | 283.12% |
| 2015 FY | 5.54 Million USD | -19.16% |
| 2015 Q4 | 5.54 Million USD | -13.32% |
| 2015 Q3 | 6.39 Million USD | 5.2% |
| 2015 Q2 | 6.08 Million USD | -10.22% |
| 2015 Q1 | 6.77 Million USD | -1.25% |
| 2014 FY | 6.85 Million USD | -42.67% |
| 2014 Q2 | 6.98 Million USD | -36.48% |
| 2014 Q3 | 7.21 Million USD | 3.3% |
| 2014 Q4 | 6.85 Million USD | -4.88% |
| 2014 Q1 | 10.98 Million USD | -8.13% |
| 2013 Q1 | 6.53 Million USD | -8.32% |
| 2013 Q2 | 7.51 Million USD | 15.03% |
| 2013 Q3 | 11.33 Million USD | 50.73% |
| 2013 Q4 | 11.96 Million USD | 5.58% |
| 2013 FY | 11.96 Million USD | 67.82% |
| 2012 Q3 | 6.9 Million USD | -5.02% |
| 2012 Q4 | 7.12 Million USD | 3.23% |
| 2012 FY | 7.12 Million USD | 237.18% |
| 2012 Q1 | 6.91 Million USD | 227.2% |
| 2012 Q2 | 7.27 Million USD | 5.1% |
| 2011 Q2 | 3.3 Million USD | -5.07% |
| 2011 Q1 | 3.47 Million USD | 71.3% |
| 2011 Q3 | 2.18 Million USD | -33.72% |
| 2011 Q4 | 2.11 Million USD | -3.43% |
| 2011 FY | 2.11 Million USD | 4.08% |
| 2010 Q3 | 1.52 Million USD | 2.34% |
| 2010 Q4 | 2.03 Million USD | 32.9% |
| 2010 FY | 2.03 Million USD | -58.18% |
| 2010 Q1 | 12.46 Million USD | 156.56% |
| 2010 Q2 | 1.49 Million USD | -88.02% |
| 2009 Q3 | 4.64 Million USD | -1.78% |
| 2009 Q2 | 4.73 Million USD | 221.09% |
| 2009 Q1 | 1.47 Million USD | -18.52% |
| 2009 FY | 4.85 Million USD | 168.57% |
| 2009 Q4 | 4.85 Million USD | 4.53% |
| 2008 Q4 | 1.8 Million USD | -20.92% |
| 2008 Q2 | 2.16 Million USD | 31.31% |
| 2008 Q1 | 1.64 Million USD | 18.93% |
| 2008 FY | 1.8 Million USD | 30.54% |
| 2008 Q3 | 2.28 Million USD | 5.71% |
| 2007 Q2 | 831.21 Thousand USD | 18.78% |
| 2007 Q3 | 677.16 Thousand USD | -18.53% |
| 2007 Q4 | 1.38 Million USD | 104.59% |
| 2007 FY | 1.38 Million USD | 63.28% |
| 2007 Q1 | 699.77 Thousand USD | -17.52% |
| 2006 FY | 848.46 Thousand USD | 11529.17% |
| 2006 Q3 | 31.54 Thousand USD | 57.45% |
| 2006 Q2 | 20.03 Thousand USD | 0.0% |
| 2006 Q1 | 20.03 Thousand USD | 0.0% |
| 2006 Q4 | 848.46 Thousand USD | 2589.35% |
| 2005 FY | 7296.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -19135.957% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 44.253% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 92.718% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -552.453% |
| Rebus Holdings, Inc. | 5.24 Million USD | -0.668% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 91.058% |
| Qrons Inc. | 1.48 Million USD | -254.467% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -330.349% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 92.956% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -11706.426% |
| Skye Bioscience, Inc. | 14.07 Million USD | 62.501% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 90.1% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 44.928% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1151.755% |
| SQZ Biotechnologies Company | 50.03 Million USD | 89.454% |
| Intellipharmaceutics International Inc. | 12 Million USD | 56.057% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -37.014% |
| Mesoblast Limited | 188.44 Million USD | 97.2% |
| Marizyme, Inc. | 26.67 Million USD | 80.218% |
| Genus plc | 485 Million USD | 98.912% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 9.681% |
| Pharming Group N.V. | 244.07 Million USD | 97.838% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -162.52% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -109.71% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -38.868% |
| ContraFect Corporation | 32.53 Million USD | 83.779% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -166.339% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -37.865% |
| IMV Inc. | 37.93 Million USD | 86.089% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 55.197% |
| MultiCell Technologies, Inc. | 1617.67 USD | -326109.919% |
| ONE Bio Corp. | 27.49 Million USD | 80.808% |
| Accustem Sciences Inc. | 1.07 Million USD | -388.956% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 93.184% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -149.495% |
| Q BioMed Inc. | 8.13 Million USD | 35.116% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.637% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -2.545% |
| Biomind Labs Inc. | 1.49 Million USD | -252.126% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.555% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 41.64% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 71.326% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -268.027% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3613.713% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2523.859% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 8.159% |
| GB Sciences, Inc. | 5.41 Million USD | 2.594% |
| Alpha Cognition Inc. | 7.16 Million USD | 26.348% |
| HST Global, Inc. | 593.59 Thousand USD | -788.993% |
| CSL Limited | 18.62 Billion USD | 99.972% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -319.078% |
| Halberd Corporation | 728.71 Thousand USD | -624.147% |
| Enzolytics Inc. | 365.26 Million USD | 98.555% |
| Agentix Corp. | 2.51 Million USD | -110.193% |
| Resverlogix Corp. | 67.39 Million USD | 92.17% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -529.164% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.814% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -207.876% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 78.675% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 55.667% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -43.977% |
| AVAX Technologies, Inc. | 3.99 Million USD | -32.132% |
| Zenith Capital Corp. | 27.56 Thousand USD | -19041.064% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.602% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2111.151% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -41.311% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -675.079% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -94.605% |
| Kadimastem Ltd | 3.5 Million USD | -50.562% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -7784.475% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 89.501% |
| BioStem Technologies, Inc. | 15.9 Million USD | 66.821% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1035.574% |
| LadRx Corporation | 2.2 Million USD | -139.806% |
| Cell Source, Inc. | 15.8 Million USD | 66.615% |
| Regen BioPharma, Inc. | 5.45 Million USD | 3.309% |
| Regen BioPharma, Inc. | 5.45 Million USD | 3.309% |
| NovAccess Global Inc. | 7.86 Million USD | 32.869% |
| Affymax, Inc. | 8.87 Million USD | 40.514% |
| Itoco Inc. | 1.65 Million USD | -219.209% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -157.218% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 12.762% |
| Mobile Lads Corp. | 1.31 Million USD | -301.752% |
| CytoDyn Inc. | 127.89 Million USD | 95.874% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -12524.704% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -236.892% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 52.224% |
| SYBLEU INC | 681.41 Thousand USD | -674.42% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 13.519% |
| Bioxytran, Inc. | 3.24 Million USD | -62.394% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -743.229% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -14.292% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 87.128% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 76.299% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -160.543% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 3.669% |
| Neutra Corp. | 973.52 Thousand USD | -442.049% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 81.813% |
| PureTech Health plc | 125.58 Million USD | 95.798% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -40.453% |
| IXICO plc | 1.9 Million USD | -177.694% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 74.295% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.893% |
| CSL Limited | 18.62 Billion USD | 99.972% |
| Cellectis S.A. | 249.36 Million USD | 97.884% |